Today, April 20, 2026, is the final day for stakeholders to submit comments on HRSA’s Request for Information (RFI) regarding the potential 340B Rebate Model Pilot Program. The agency originally gave stakeholders just 30 days to respond; but after pressure from hospital associations and safety-net providers, HRSA extended the window to 60 days and invited broader feedback on whether — and how — to redesign the previously paused rebate pilot.
How We Got Here
Last year, HRSA approved a manufacturer-proposed rebate pilot that would have shifted 340B pricing from upfront point-of-sale discounts to a back-end rebate model for select drugs. In early 2026, the U.S. District Court for the District of Maine vacated and remanded that pilot program, finding that HHS had failed to meet its statutory obligations. Manufacturers had to immediately restore upfront 340B discounts.
Rather than abandoning the idea, HRSA issued an RFI in February asking stakeholders to weigh in on whether a rebate model could work, how it should be structured, which drugs it should apply to, and how operational and financial impacts on patient access should be evaluated. HRSA has also signaled interest in expanding any future rebate model to encompass all drugs subject to the Inflation Reduction Act’s Medicare Drug Price Negotiation program through 2027.
If HRSA moves forward with a rebate model, covered entities will face cash-flow pressure they don’t face today, and the compliance burden will grow.
Why Covered Entities Are Pushing Back
Under a rebate model, covered entities would pay full list price upfront and have to wait, sometimes weeks or months, to recoup the 340B discount. For hospitals and clinics with thin margins, that creates immediate cash-flow strain. It also introduces new administrative overhead: claims tracking, rebate reconciliation, dispute resolution, and a higher risk of duplicate discount errors with Medicaid.
The political signal is equally clear. Earlier this month, nearly 100 bipartisan members of the House of Representatives sent a letter to HHS urging the administration not to use federal funds to implement a 340B rebate model pilot.
What Happens After Today
Once the comment window closes, HRSA will review submissions and decide whether to move forward with a revised pilot, revise the design further, or set the concept aside. The agency is unlikely to issue a final decision quickly, but covered entities should assume that some form of rebate infrastructure will be on the table again within the next 12 to 18 months.
In the meantime, two things are worth watching. First, CMS’s ongoing drug acquisition cost survey, which feeds directly into how 340B ceiling prices are calculated. Second, continued manufacturer actions, including restrictions on contract pharmacy arrangements, that effectively narrow 340B savings regardless of what HRSA does with the rebate model.
What This Means for Your Organization
Whether the pressure comes from a future rebate pilot, state Medicaid policy changes, or manufacturer-imposed contract pharmacy restrictions, the 340B program is being reshaped around you in real time.
This is exactly where a Premium Insurance Assistance Program (PIAP) becomes a strategic advantage. Rather than leaving 340B savings exposed to policy volatility, a PIAP reinvests those dollars into enrolling eligible patients in ACA Marketplace coverage.
When your patients are enrolled in private insurance through PIAP, your organization builds a diversified, stable revenue foundation. Even if rebate timing changes or 340B discounts are narrowed, commercially insured patients continue to generate revenue, keeping services funded and expanding your capacity to serve more of the community. And most importantly, it ensures your patients have continuous, affordable access to the care they need.
Schedule time to learn how PIAP can support long-term access and stability for your patients.
